WST

NEUTRALProduct

West Pharmaceutical Services, I

2026-09-23

Price

$375.87

+9.19%

This is the 2026-09-23 snapshot — the signals and analysis for WST as of this single trading day.

View full WST research hub →

Score9.5Priority

Signals4/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.6xvs 20d avg

Analysis

WST is surging because secular tailwinds in GLP-1 delivery systems and regulatory Annex 1 sterility upgrades are driving aggressive institutional accumulation. Despite headline noise surrounding a recent cyber incident, tariff pressures, and the winding down of its Arizona SmartDose facility, the stock is exhibiting a powerful BREAKOUT with urgent volume at 1.6x its average. In a highly constructive RISK_ON macro regime where broader equities are ignoring rate pressures, WST's PERFECT_STACK technical setup and resilient High-Value Product (HVP) demand confirm High-Conviction Price Discovery and institutional absorption of any fundamental noise.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONBREAKOUT

Key Takeaways

Actionable Thesis: WST is a high-conviction momentum buy as it breaks out to new highs, fueled by GLP-1 exposure and a recent Barclays Overweight upgrade to a $400 price target.
Key Risk: Margin compression from tariff-related cost inflation or lingering operational impacts from the recent West Vantage cyber incident.
What to Watch: Monitor the $328.20 line-in-the-sand level for technical support and watch for updates on the 340+ Annex 1 regulatory project conversions.

← Back to 2026-09-23 View Full WST History →Yahoo Finance &nearr;